Grail
Grail's revenue rose 17.2% to $147 million in fiscal 2025. Its operating margin was −382.0%, up from −1,743.0% a year earlier. Free cash flow was −$300 million. The diluted share count rose 15.2%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Grail does
GRAIL sells Galleri, a blood test that screens for many types of cancer at once and points to where in the body a cancer signal may have come from. The company describes itself as commercial-stage, meaning the test is already on sale. Galleri is currently offered through partnerships with healthcare systems, employers, digital health platforms, payors and life insurance providers.
Almost all of its revenue comes from Galleri. GRAIL says it has run what it believes is the largest clinical program in genomic medicine, and it has submitted a pre-market approval application to the U.S. Food and Drug Administration, with the last part sent in January 2026. It reported results from two large studies, PATHFINDER 2 and the NHS-Galleri trial, and included some of them in that application.
The NHS-Galleri trial did not meet its main goal, which the company lists as a risk. GRAIL has a limited operating history and has lost money in every period since it began.
Its biggest risks, as it describes them
- A substantial majority of its revenue comes from Galleri, so it depends heavily on one test.
- The NHS-Galleri trial did not meet its main goal, which may hurt its business and its approval efforts.
- Insurers and other payors may not cover Galleri or may pay too little for it.
- The test may not perform in real-world use as it did in clinical studies.
- It has lost money in every period since it began and expects more net losses.
Income statement
Grail lost money in fiscal 2025: a net loss of $408 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Cash and short-term investments | 242 | 97 | 761 | 902 |
| Debt incl. finance leases | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — |
| Net debt to EBITDA | — | — | — | — |
| Debt to equity | — | — | — | — |
| Interest coverage | — | — | — | — |
| Current ratio | — | 0.9x | 10.7x | 12.0x |
| Quick ratio | — | 0.9x | 10.7x | 12.0x |
Cash flow
Projections
Project Grail's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Grail shares on the open market, and 5 insiders sold $110.6 million, $7.5 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 21, 2026 | Joshua J. OfmanChief Executive Officer, Director | Sold plan | 61,452 | $97.74 | $6.0 million | Form 4 |
| Sep 21, 2026 | Aaron FreidinChief Financial Officer | Sold plan | 4,100 | $93.34 | $382,682 | Form 4 |
| Aug 27, 2026 | Aaron FreidinChief Financial Officer | Sold plan | 7,900 | $85.01 | $671,579 | Form 4 |
| Aug 27, 2026 | Joshua J. OfmanChief Executive Officer, Director | Sold plan | 5,000 | $85.02 | $425,100 | Form 4 |
| Jun 4, 2026 | Andrew John PartridgeChief Growth Officer | Sold | 1,491 | $61.08 | $91,070 | Form 4 |
| Apr 8, 2026 | Robert P RagusaChief Executive Officer, Director | Sold | 123,502 | $49.92 | $6.2 million | Form 4 |
| Apr 8, 2026 | Joshua J. OfmanPresident, Director | Sold | 61,665 | $49.92 | $3.1 million | Form 4 |
| Apr 8, 2026 | Aaron FreidinChief Financial Officer | Sold | 45,806 | $49.92 | $2.3 million | Form 4 |
| Mar 9, 2026 | Robert P RagusaChief Executive Officer, Director | Sold | 7,461 | $47.89 | $357,296 | Form 4 |
| Mar 9, 2026 | Joshua J. OfmanPresident | Sold | 2,937 | $47.89 | $140,650 | Form 4 |
| Mar 9, 2026 | Aaron FreidinChief Financial Officer | Sold | 2,492 | $47.89 | $119,340 | Form 4 |
| Mar 5, 2026 | Robert P RagusaChief Executive Officer, Director | Sold | 980 | $53.01 | $51,950 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −586.2% | −428.8% | −186.6% |
| Altman Z'' | — | −8.53 | −2.86 |
| Accruals ratio | — | −42.0% | −3.7% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | — | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | — | — | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | — | Pass | Pass |
| Share count didn't rise | Pass | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | — | Pass |
| F-score | — | — | — |
Compare
Put Grail side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Grail | FY25 | 17.2% | −382.0% | −203.8% | — | — | — | |
| Schrödinger | FY25 | 23.3% | −65.2% | 4.9% | — | — | — | Compare |
| Castle Biosciences | FY25 | 3.7% | −12.4% | 8.2% | −19.1% | — | 4 | Compare |
| CareDx | FY25 | 13.8% | −8.1% | — | −20.0% | — | 4 | Compare |
| GeneDx | FY25 | 40.0% | −3.1% | 3.3% | −5.3% | — | 6 | Compare |
4 years of figures
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 56 | 93 | 126 | 147 |
| Revenue growth | — | 67.6% | 34.9% | 17.2% |
| Gross profit | — | — | — | — |
| Research and development | 330 | 339 | 322 | 196 |
| Operating income | −5,443 | −1,515 | −2,189 | −562 |
| Net income | −5,399 | −1,466 | −2,027 | −408 |
| Diluted EPS (US$) | −173.89 | −47.21 | −63.54 | −11.11 |
| Diluted shares (millions) | 31 | 31 | 32 | 37 |
| Cash flow | ||||
| Cash from operations | −561 | −596 | −577 | −299 |
| Capital expenditure | 23 | 13 | 5 | 1 |
| Free cash flow | −584 | −609 | −582 | −300 |
| Dividends paid | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 |
| Stock-based compensation | 76 | 97 | 86 | 58 |
| Balance sheet at fiscal year end | ||||
| Cash and short-term investments | 242 | 97 | 761 | 902 |
| Debt incl. finance leases | — | — | — | — |
| Total assets | — | 3,914 | 2,983 | 2,922 |
| Total liabilities | — | 268 | 480 | 344 |
| Shareholders' equity | — | — | 2,503 | 2,578 |
| Margins and ratios | ||||
| Gross margin | — | — | — | — |
| Operating margin | −9,798.2% | −1,627.6% | −1,743.0% | −382.0% |
| Net margin | −9,719.4% | −1,574.2% | −1,613.9% | −277.5% |
| Free cash flow margin | −1,051.6% | −653.8% | −463.7% | −203.8% |
| Rule of 40 (growth + FCF margin) | — | −586.2% | −428.8% | −186.6% |
| Return on capital | — | — | — | — |
| Return on equity | — | — | — | −16.1% |
| Return on assets | — | — | −58.8% | −13.8% |
| Net debt to EBITDA | — | — | — | — |